Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master Protocol for Multiple Interventions in Chronic Pain
NCT05986292Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Fepixnebart, ly3556050, LY3526318, RQ-00466479 and LY4065967 in osteoarthritis (OA), diabetic neuropathy and chronic low back pain (CLBP), sponsored by Eli Lilly and Company. Started Jan 2020; status: recruiting.
02
Drugs
Fepixnebartly3556050LY3526318RQ-00466479LY4065967
03
Conditions
osteoarthritis (OA)diabetic neuropathychronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT05986292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986292.